Rybelsus (oral semaglutide) is FDA-approved for type 2 diabetes only — not for weight loss. See the real PIONEER weight numbers, the ~$998/month cash price, why insurance rarely covers off-label use, and how PlexusDx Semaglutide Oral ($209/mo+) and the Microdose GLP-1 Protocol ($129/mo) compare on cost and dose flexibility.

Retatrutide (Lilly's investigational triple agonist) and orforglipron (Lilly's oral non-peptide GLP-1) are the two big pipeline stories in 2026 — but neither is FDA-approved yet. Here's the realistic timeline, the Phase 3 data, the announced and unknown pricing, and how PlexusDx's currently-available compounded semaglutide and tirzepatide protocols ($129–$509/mo) compare for someone who needs an option today rather than in 2028.

Is oral tirzepatide FDA approved? No — only injectable Mounjaro and Zepbound are. Here's what compounded oral tirzepatide is, how PlexusDx Tirzepatide Oral ($229–$509/mo) fits, and the safety considerations that apply to both.

Oral semaglutide vs injectable semaglutide in 2026: Rybelsus, the new Wegovy pill, Ozempic, and Wegovy injection compared on dose, bioavailability, effectiveness, and cost — plus where PlexusDx Semaglutide Oral ($209/mo+), Semaglutide Injection ($179–$229/mo), and Microdose GLP-1 Protocol ($129/mo flat) fit as cash-pay alternatives covering both pill and shot formats.

Mounjaro side effects from the FDA-approved label — common GI reactions (nausea, vomiting, diarrhea, constipation, abdominal pain), less common serious reactions (pancreatitis, gallbladder disease, acute kidney injury), and the boxed warning for thyroid C-cell tumors with MTC and MEN 2 contraindications. Plus how compounded tirzepatide protocol oversight from PlexusDx Tirzepatide Injection ($229–$309/mo) and Tirzepatide Oral ($229–$509/mo) compares, and where the Precision Peptide Genetic Test fits as a $99 add-on for GLP1R, GIPR, FTO, MC4R, and TCF7L2 baseline.

MEDVi vs TrimRx vs PlexusDx in 2026: real cash-pay GLP-1 pricing, compounded vs branded, multi-month upfront vs month-to-month, and where genetic testing changes the dose conversation before week one.

MEDVi vs Ro vs PlexusDx for cash-pay GLP-1 weight loss: real annualized cost math, compounded vs FDA-approved branded, safety considerations, and where genetic baselining changes the dose decision before week one.

MEDVi, Remedy Meds, and PlexusDx all dispense compounded semaglutide and tirzepatide — but the annualized cost, billing cadence, and clinical-oversight model differ in ways the landing pages don't show. This guide walks the real numbers, the September 2025 FDA warning-letter context, and where PlexusDx Weight Management Protocols ($129–$325/mo) plus the Precision Peptide Genetic Test fit relative to both.

MEDVi vs Lilly Direct vs PlexusDx in 2026: all-inclusive compounded telehealth, FDA-approved Zepbound at self-pay vial pricing, and a genetics-anchored compounded protocol. Real 12-month math, the 45-day refill trap, and where each fits.

MEDVi vs Hims vs PlexusDx in 2026: MEDVi at $179 first month then $299/mo with no contract, Hims at $199/mo gated behind a $1,194 six-month prepayment, and PlexusDx Weight Management Protocols from $129/mo with no upfront commitment and an optional Precision Peptide Genetic Test for genetic-guided GLP-1 dosing.

MEDVi vs Hers vs PlexusDx in 2026: real annual cost math, compounded vs FDA-approved branded medication source, tirzepatide availability across all three, cancellation and refund policy differences, and where the Precision Peptide Genetic Test fits when GLP-1 response varies by GLP1R, GIPR, FTO, MC4R, and TCF7L2 variants.

MEDVi vs Gala GLP-1 vs PlexusDx compared on verified 2026 pricing, compounded vs FDA-approved status, cancellation rules, and where a genetic baseline changes the dose decision before week one.

MEDVi semaglutide ranges from $149 to $299/month depending on which page you land on. We reconcile every published MEDVi rate against PlexusDx Semaglutide Injection ($179-$229/mo) and Semaglutide Oral (from $209/mo) on a 12-month total-cost basis — with the genetic baseline MEDVi doesn’t offer.

MEDVi sells two different oral GLP-1 products under one banner: a compounded semaglutide tablet from $249/month and a Wegovy pill route at $99/month membership plus medication. We unpack the pricing, the FDA regulatory status, the 72-hour cancellation rule, and where PlexusDx Semaglutide Oral ($209/mo+) and Microdose GLP-1 Protocol ($129/mo flat) fit for cash-pay readers who want a non-injection GLP-1.

Is SHED legit? Yes — verified LLC, named pharmacy partners, 875+ reviews — but with a 2-month minimum and 72-hour cancellation cutoff. Compare SHED to PlexusDx Weight Management Protocols: month-to-month, no membership, with optional Precision Peptide Genetic Test before titration.

Is GLP-1 HRA, FSA, or HSA eligible? Often yes when prescribed for a diagnosed condition, but the rules vary by plan. Here is the framework, the documentation you need, and where PlexusDx Weight Management Protocols (from $129/mo, all 50 states, no membership) fit when your account does not cover GLP-1s for weight loss.

Florida residents can legally start GLP-1 telehealth in days under Statute §456.47. We compare MEDVi, Ro, Walgreens, and the PlexusDx Microdose GLP-1 Protocol from $129/mo — with a genetic baseline option no other Florida provider offers.

Constipation is one of the most common GLP-1 side effects — here's the food, fluid, movement, and dose-adjustment playbook that actually works, plus where the PlexusDx Microdose GLP-1 Protocol and Precision Peptide Genetic Test fit in.

A GLP-1 program under $300/month is real in 2026 if you pick a structure that doesn't reset in month two. Four PlexusDx protocols stay under the cap at every published dose tier: Microdose GLP-1 Protocol at $129/mo flat, Semaglutide Injection at $179–$229/mo, Tirzepatide Injection from $229/mo, and GLP-Squared from $179/mo — all cash-pay, all-inclusive, no membership.

Eight GLP-1 programs publish verified outcome-based money-back guarantees as of April 2026 — Eden, SHED, Brightmeds, Fella Health, RemedyMeds, Calibrate, Aayu Well, and LifeMD — each with 6–12 month windows and structured adherence requirements. PlexusDx does not offer an outcome guarantee but prices flat with no membership and no required commitment, so risk is bounded by one month of cost rather than by a 6–12 month adherence schedule.

What's common, what's serious, and how to manage GLP-1 side effects from FDA-labeled known information — including the boxed warning that applies to both semaglutide and tirzepatide, when to call your provider, and how PlexusDx structures titration and the optional Precision Peptide Genetic Test.

The honest list of GLP-1 options under $200/mo in April 2026 is much shorter than the ads suggest. PlexusDx Microdose GLP-1 Protocol at $129/mo flat is the lowest under-$200 option in this comparison, with PlexusDx Semaglutide Injection at $179/mo entry tier as the lowest weekly compounded semaglutide path. FDA-approved Foundayo and the Wegovy pill start at $149/mo at lower doses but escalate with dose; most other “$199 GLP-1” ads are first-month-only promos that jump to $249–$349 on refill.

Wellness stipends typically reimburse GLP-1 programs through receipt upload, not direct employer billing. PlexusDx accepts payment from cards issued under wellness stipend and LSA programs (Compt, Forma, Espresa, Fringe, Benepass, PeopleKeep) and provides itemized receipts — but does not bill employers directly. Stipend eligibility depends on your employer's plan language, especially around “FDA-approved” vs “prescription medication” phrasing for compounded GLP-1s.

Pennsylvania Medicaid cut GLP-1 coverage for adult weight loss on January 1, 2026. This guide walks the legal cash-pay telehealth options that ship to PA, the compounded vs FDA-approved branded distinction, real annualized costs, and where PlexusDx Microdose GLP-1 ($129/mo), Semaglutide Injection ($179–$229/mo), and Tirzepatide Injection ($229–$309/mo) sit relative to Eden, Ro, TrimRx, Willow, and MEDVi — with the optional Precision Peptide Genetic Test anchoring dose decisions to your DNA before week one.

Ohio's GLP-1 coverage fractured in 2025-2026 — State of Ohio employee plan, OSU Health Plan, and Ohio Medicaid all narrowed weight-loss GLP-1 access. This guide walks the cash-pay landscape, Ohio telehealth law, compounded vs FDA-approved options, and where PlexusDx Weight Management Protocols ($129/mo flat to $309/mo) fit for Ohio residents.

NH Medicaid dropped GLP-1 weight-loss coverage on January 1, 2026. Here’s the cash-pay landscape for New Hampshire residents in 2026 — telehealth eligibility, real prices from $129 to $1,349/mo, compounded vs FDA-approved trade-offs, and where PlexusDx Weight Management Protocols fit.

Kentucky residents have three paths to GLP-1 weight-loss therapy in 2026: brand-name FDA-approved medication (Wegovy, Zepbound) at retail or Lilly Direct, in-person clinical care through systems like UK HealthCare Turfland, and cash-pay compounded telehealth. Kentucky Medicaid does not cover GLP-1 for weight loss. PlexusDx Weight Management Protocols ship to all 120 Kentucky counties from $129/mo flat with no membership fee.

The full 2026 GLP-1 cost map: Wegovy, Ozempic, Zepbound, and Mounjaro at branded list price; Lilly Direct and NovoCare manufacturer self-pay programs ($149–$499/mo); cash-pay compounded telehealth alternatives. PlexusDx Weight Management Protocols span $129–$509/mo with all-inclusive pricing, no membership, all 50 states.

Foundayo's $149 headline is a one-month starter price — the real cash-pay year runs $3,338–$3,738 once you escalate. Compare PlexusDx Microdose GLP-1 ($129/mo flat), Semaglutide Oral ($209+/mo), and Tirzepatide Oral ($229+/mo) on annualized cost.

Foundayo costs $25/month with covered commercial insurance, $50/month on the Medicare GLP-1 Bridge, or $149–$349/month self-pay through LillyDirect. Most commercial plans don't cover GLP-1s for weight loss in 2026. Compare cash-pay PlexusDx Weight Management Protocols — Microdose at $129/mo flat, Semaglutide Injection $179–$229/mo, Tirzepatide Injection $229–$309/mo — with no membership fee.